Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

False-positive cancer screens and health-related quality of life.

McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR.

Cancer Nurs. 2004 Sep-Oct;27(5):347-52.

PMID:
15525861
2.

The economic impact of false-positive cancer screens.

Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2126-32.

3.

Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Weissfeld JL, Fagerstrom RM, O'Brien B; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):390S-399S.

PMID:
11189690
4.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683
5.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

PMID:
15770007
6.

Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Stallings FL, Ford ME, Simpson NK, Fouad M, Jernigan JC, Trauth JM, Miller DS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S.

PMID:
11189689
7.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S.

PMID:
11189684
8.

Distressed or relieved? Psychological side effects of breast cancer screening in The Netherlands.

Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel WJ.

J Epidemiol Community Health. 1997 Dec;51(6):705-10.

9.

Short-term effects of population-based screening for prostate cancer on health-related quality of life.

Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schröder FH.

J Natl Cancer Inst. 1998 Jun 17;90(12):925-31.

PMID:
9637143
10.

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Project Team.

J Urol. 2005 Mar;173(3):746-50; discussion 750-1.

PMID:
15711261
11.

Systematic review: the long-term effects of false-positive mammograms.

Brewer NT, Salz T, Lillie SE.

Ann Intern Med. 2007 Apr 3;146(7):502-10. Review.

PMID:
17404352
12.

Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial.

Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J.

J Clin Oncol. 2005 Dec 1;23(34):8730-8.

PMID:
16314633
13.

Socioeconomic status differences in coping with a stressful medical procedure.

Simon AE, Steptoe A, Wardle J.

Psychosom Med. 2005 Mar-Apr;67(2):270-6.

PMID:
15784793
14.

Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial).

van den Bergh KA, Essink-Bot ML, Bunge EM, Scholten ET, Prokop M, van Iersel CA, van Klaveren RJ, de Koning HJ.

Cancer. 2008 Jul 15;113(2):396-404. doi: 10.1002/cncr.23590.

15.

Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Miller AB, Yurgalevitch S, Weissfeld JL; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):400S-406S.

PMID:
11189691
16.

Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

O'Brien B, Nichaman L, Browne JE, Levin DL, Prorok PC, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):310S-328S.

PMID:
11189685
17.

Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.

Simpson NK, Johnson CC, Ogden SL, Gamito E, Trocky N, McGuire C, Martin J, Barrow S, Lamerato L, Flickinger LM, Broski KG, Engelhard D, Hilke C, Bonk J, Gahagan B, Gren LH, Childs J, Lappe K, Fouad M, Thompson J, Sullivan D; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):356S-378S.

PMID:
11189688
18.

Psychological reactions in men screened for prostate cancer.

Gustafsson O, Theorell T, Norming U, Perski A, Ohström M, Nyman CR.

Br J Urol. 1995 May;75(5):631-6.

PMID:
7613800
19.

An object lesson: source determines the relations that trait anxiety, prostate cancer worry, and screening fear hold with prostate screening frequency.

Consedine NS, Adjei BA, Ramirez PM, McKiernan JM.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1631-9. doi: 10.1158/1055-9965.EPI-07-2538.

20.

Changes in cancer worry associated with participation in ovarian cancer screening.

Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Lowe KA, Urban N.

Psychooncology. 2007 Sep;16(9):814-20.

PMID:
17225260

Supplemental Content

Support Center